Ronald Cahill, Partner, Barnes & Thornburg LLP to Speak at The Knowledge Group’s Biotech and Pharmaceutical Patent Law
The Knowledge Group, the leading producer of regulatory-focused webcasts, has announced today that Ronald Cahill, Partner, Barnes & Thornburg LLP will speak at its webcast entitled, “Biotech and Pharmaceutical Patent Law: Cutting-Edge Issues to Watch For.”
- (1888PressRelease) September 16, 2022 - This event is scheduled for September 16, 2022 from 12:00 PM to 1:30 PM ET.
For further details, please visit: https://knowledgewebcasts.com/know-portfolio/biotech-and-pharmaceutical-patent-law-cle/
About Ronald Cahill
Ron Cahill is well-respected for his work with clients of virtually all sizes to solve their most challenging intellectual property problems. A first-chair IP trial attorney and Chair of the Barnes & Thornburg national Life Sciences Practice Group, he specializes in breaking down complex life sciences intellectual property issues for juries, judges, and the PTAB. Clients also ask him to present strategic intellectual property options to their management and boards, including whether to launch litigation and how to gain leverage in business, investment, and licensing negotiations.
Ron’s work covers a wide range of life sciences products, technologies, and legal issues, with recent engagements including CAR-T cancer treatments, small molecule enzyme inhibitors, personalized medicine, and genetic engineering of metabolic systems to produce desired outputs. Recent legal issues have included the scope of written description and enablement in the drug discovery context, the obviousness of engineered biologics, infringement based on biochemical function and property limitations, induced infringement of method of treatment claims, and the strategic use of IPRs to avoid litigation.
About Barnes & Thornburg LLP
Barnes & Thornburg LLP is a national, full-service law firm representing clients ranging from Fortune 500 corporations to entrepreneurial growth companies. We provide services in more than 50 areas, including litigation, labor and employment, global services, healthcare, governmental services and finance, intellectual property, environmental, business, construction, white collar crime, life sciences, real estate, energy, telecommunications, transportation and utilities; and finance insolvency and restructuring. With more than 700 attorneys and other legal professionals, Barnes & Thornburg is one of the largest law firms in the country. The firm serves clients worldwide from offices in Atlanta, Boston, California, Chicago, Delaware, Indiana, Michigan, Minneapolis, New York, Ohio, Raleigh, Salt Lake City, Texas and Washington, D.C.
Event Summary
Several court cases continue to shape the biotech and pharmaceutical patent litigation in the United States and Canada.
In the United States, Amgen Inc. v. Sanofi-Aventis (2021) has revived the discussion on the enablement of genus claims in biotechnology inventions. Moreover, the multiple filings for abbreviated new drug applications (ANDA) also raise concerns, particularly in cases that may provoke multidistrict litigation. These and other developments further expand the patent litigation landscape, introducing new regulations that practitioners must be aware of to avoid legal pitfalls.
In Canada, summary trials are increasingly affecting the way litigation is proceeding. Issues concerning cases that impact the scope of the Notice of Allegation, certificates of supplementary protection, and the Patent Medicines Price Review Board, as well as those relating to claim construction, obviousness, and patentable subject matter, must be considered.
Join a panel of key thought leaders and distinguished professionals organized by The Knowledge Group as they provide a comprehensive discussion of the recent litigation trends in the biotech and pharmaceutical industry. Speakers, among other things, will also offer practical tips and strategies in this ever-changing regulatory landscape.
Key Topics include:
• Recent Litigation Trends and Developments in the Biotech and Pharmaceutical Industry
• Enablement of Genus Claims for Biotechnology Inventions
• Multiple Filing of Abbreviated New Drug Applications (ANDA): Implications
• Recent and Notable Court Cases
• What Lies Ahead
About The Knowledge Group
Founded in November 2006, The Knowledge Group has been at the forefront of providing quality continuing education programs for lawyers, accountants, financial executives, risk and compliance specialists, human resources professionals, technology officers, and business consultants in a wide range of industries.
The Knowledge Group strives to be the best-in-class provider of continuing education by bringing forth relevant content you can’t get anywhere else.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam